The rise and fall of the “minimum clinically important difference”
No abstract is available. To read the body of this article, please view the Full Text online.
To access this article, please choose from the options below
FDA device/drug status: not applicable.
Author disclosures: EJC (stock ownership, including options and warrants, Simpirica, Bioassetts, Cytonics; private investments, including venture capital, start-ups, Simpirica; consulting, Medtronic, Synthes, Well-Point B/C B/S; trips/travel, US army; scientific advisory board, Intrinsic Orthopedics, Cytonics; other office, Bioassetts; grants, AO Foundation; fellowship support, DePuy Spine; other relationships, Orthopaedic Surgeon).
PII: S1529-9430(10)00117-8
doi:10.1016/j.spinee.2010.02.013
© 2010 Elsevier Inc. All rights reserved.
